De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review)

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].

Original languageEnglish
Pages (from-to)691-695
Number of pages5
JournalDigestive Diseases and Sciences
Volume59
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Nephritis
Chronic Hepatitis
Interferons
Ribavirin
Therapeutics
Antiviral Agents
End Stage Liver Disease
Hepatocellular Carcinoma
Clinical Trials
Population

Keywords

  • Hepatitis C
  • Interferon
  • Membrano-proliferative glomerulonephritis
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

@article{de65d8521f744cbab3a8c00cc340ab06,
title = "De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review)",
abstract = "HCV infects approximately 2-3 {\%} of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 {\%} of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 {\%} of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 {\%} (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].",
keywords = "Hepatitis C, Interferon, Membrano-proliferative glomerulonephritis, Ribavirin",
author = "Fabrizio Fabrizi and Alessio Aghemo and Gabriella Moroni and Patrizia Passerini and Roberta D'Ambrosio and Paul Martin and Piergiorgio Messa",
year = "2014",
month = "3",
doi = "10.1007/s10620-013-2959-4",
language = "English",
volume = "59",
pages = "691--695",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review)

AU - Fabrizi, Fabrizio

AU - Aghemo, Alessio

AU - Moroni, Gabriella

AU - Passerini, Patrizia

AU - D'Ambrosio, Roberta

AU - Martin, Paul

AU - Messa, Piergiorgio

PY - 2014/3

Y1 - 2014/3

N2 - HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].

AB - HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].

KW - Hepatitis C

KW - Interferon

KW - Membrano-proliferative glomerulonephritis

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84896728698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896728698&partnerID=8YFLogxK

U2 - 10.1007/s10620-013-2959-4

DO - 10.1007/s10620-013-2959-4

M3 - Article

C2 - 24318802

AN - SCOPUS:84896728698

VL - 59

SP - 691

EP - 695

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -